61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
BioMarin Pharmaceutical Inc
Closed
Sector Healthcare
62 -0.96
Overview
Share price change
24h
Min
61.58
Max
62.57
Income | -1.1M 106M |
|---|---|
Sales | 34M 746M |
P/E Sector Avg | 39.533 59.526 |
EPS | 0.91 |
Profit margin | 14.22 |
EBITDA | -29M 133M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +55.13 upside |
Next Earnings | 20 Feb 2025 |
|---|
Market Cap | -666M 12B |
|---|---|
Previous open | 62.96 |
Previous close | 62 |
News Sentiment
By Acuity
25%
75%
50 / 392 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
BioMarin Pharmaceutical Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
BioMarin Pharmaceutical Inc Forecast
Price Target
By TipRanks
55.13% upside
12 Months Forecast
Average 97 USD 55.13%
High 127 USD
Low 65 USD
Based on 25 Wall Street analysts offering 12 month price targets forBioMarin Pharmaceutical Inc - Dist in the last 3 months.
Sentiment
By Acuity
50 / 392 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About BioMarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.
